FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Grasping the Essence of Precision Medicine Signatures

NextEdge Admin

08 Oct 2023

4 min 49 sec

In precision medicine, signatures refer to specific characteristics, patterns, or markers that can be identified in patients to tailor medical care to their individual needs. These signatures can be derived from various sources, including genomic, proteomic, radiomic, and clinical data. Here are several types of signatures in precision medicine:

Genomic Signatures:

Genomic Alterations: Mutations, single nucleotide polymorphisms (SNPs), and other genetic variations that are associated with disease susceptibility, prognosis, or response to treatment.
Pharmacogenomic Signatures: Genetic markers that predict an individual’s response to specific drugs, helping to optimize drug selection and dosage.

Proteomic Signatures:

Protein Expression Profiles: Patterns of protein expression or post-translational modifications that can be indicative of disease status, progression, or response to treatment.
Biomarkers: Specific proteins that serve as indicators of disease presence, severity, or treatment response.

Transcriptomic Signatures:

Gene Expression Profiles: Patterns of gene expression that can provide insights into the underlying biology of diseases and help identify potential therapeutic targets.
mRNA Signatures: Specific patterns of messenger RNA (mRNA) expression associated with disease subtypes or treatment response.

Epigenomic Signatures:

DNA Methylation Patterns: Changes in the methylation status of DNA that can influence gene expression and contribute to disease development or progression.
Histone Modifications: Alterations in the modification of histone proteins, affecting chromatin structure and gene regulation.

Radiomic Signatures:

Imaging Biomarkers: Quantitative features extracted from medical imaging data (radiomics) that can provide information about tumor characteristics, heterogeneity, and response to treatment.
Radiogenomic Signatures: Associations between imaging features and underlying genomic characteristics of tumors.

Clinical Signatures:

Clinical and Demographic Data: Patient-specific information such as age, sex, comorbidities, and lifestyle factors that can influence disease risk and treatment outcomes.
Clinical Scoring Systems: Composite scores or algorithms that combine multiple clinical parameters to predict disease risk, prognosis, or response to treatment.

Metabolomic Signatures:

Metabolic Profiles: Patterns of metabolite levels in biological samples, providing insights into the metabolic pathways associated with disease and potential therapeutic targets.

Microbiomic Signatures:

Microbial Composition: Patterns of microbial communities in the body, especially in the gut microbiome, that may influence disease susceptibility, progression, and treatment response.

Immune Signatures:

Immunogenomic Signatures: Associations between genomic characteristics and the immune response, providing insights into the interaction between the immune system and diseases.
Immune Cell Infiltration: Patterns of immune cell presence within the tumor microenvironment, influencing the response to immunotherapies.

Multi-Omics Signatures:

Integration of Data: Combining information from multiple omics levels (genomic, proteomic, transcriptomic, etc.) to create a comprehensive profile for a more holistic understanding of disease biology and treatment response.

These various signatures collectively contribute to the concept of precision medicine by enabling a more personalized and targeted approach to diagnosis, treatment, and patient care. Integrating information from multiple sources allows clinicians to develop tailored therapeutic strategies based on the unique characteristics of each individual.

Related Tags

Precision Medicine

Genomics

Enhancing Precision Medicine through Nanotechnology

Proteomics in the Quest for Biomarkers

Top Reviews

No reviews yet

Grasping the Essence of Precision Medicine Signatures

NextEdge Admin

08 Oct 2023

4 min 49 sec

Genomic Signatures:

Genomic Alterations: Mutations, single nucleotide polymorphisms (SNPs), and other genetic variations that are associated with disease susceptibility, prognosis, or response to treatment.
Pharmacogenomic Signatures: Genetic markers that predict an individual’s response to specific drugs, helping to optimize drug selection and dosage.

Proteomic Signatures:

Protein Expression Profiles: Patterns of protein expression or post-translational modifications that can be indicative of disease status, progression, or response to treatment.
Biomarkers: Specific proteins that serve as indicators of disease presence, severity, or treatment response.

Transcriptomic Signatures:

Gene Expression Profiles: Patterns of gene expression that can provide insights into the underlying biology of diseases and help identify potential therapeutic targets.
mRNA Signatures: Specific patterns of messenger RNA (mRNA) expression associated with disease subtypes or treatment response.

Epigenomic Signatures:

DNA Methylation Patterns: Changes in the methylation status of DNA that can influence gene expression and contribute to disease development or progression.
Histone Modifications: Alterations in the modification of histone proteins, affecting chromatin structure and gene regulation.

Radiomic Signatures:

Imaging Biomarkers: Quantitative features extracted from medical imaging data (radiomics) that can provide information about tumor characteristics, heterogeneity, and response to treatment.
Radiogenomic Signatures: Associations between imaging features and underlying genomic characteristics of tumors.

Clinical Signatures:

Clinical and Demographic Data: Patient-specific information such as age, sex, comorbidities, and lifestyle factors that can influence disease risk and treatment outcomes.
Clinical Scoring Systems: Composite scores or algorithms that combine multiple clinical parameters to predict disease risk, prognosis, or response to treatment.

Metabolomic Signatures:

Metabolic Profiles: Patterns of metabolite levels in biological samples, providing insights into the metabolic pathways associated with disease and potential therapeutic targets.

Microbiomic Signatures:

Microbial Composition: Patterns of microbial communities in the body, especially in the gut microbiome, that may influence disease susceptibility, progression, and treatment response.

Immune Signatures:

Immunogenomic Signatures: Associations between genomic characteristics and the immune response, providing insights into the interaction between the immune system and diseases.
Immune Cell Infiltration: Patterns of immune cell presence within the tumor microenvironment, influencing the response to immunotherapies.

Multi-Omics Signatures:

Integration of Data: Combining information from multiple omics levels (genomic, proteomic, transcriptomic, etc.) to create a comprehensive profile for a more holistic understanding of disease biology and treatment response.